









Markets
/
Stocks
/
nasdaq-goss
/

Gossamer Bio Inc

GOSS

2.360USD

+0.050+2.16%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

545.88MMarket Cap

LossP/E TTM



Gossamer Bio Inc

2.360

+0.050+2.16%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Gossamer Bio Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Gossamer Bio Inc's Score

Industry at a Glance

Industry Ranking

66 / 407

Overall Ranking

182 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.000

Target Price

+281.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Gossamer Bio Inc Highlights

StrengthsRisks

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Fairly Valued

The company’s latest PE is -3.43, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 178.09M shares, decreasing 23.56% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 139.41K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.63, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 13.29M, representing a year-over-year increase of 40.23%, while its net profit experienced a year-over-year increase of 56.55%.

Score

Industry at a Glance

Previous score

7.63

Change



Financials

3.98

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.46

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.41

Key Metrics

Free cash flow

No Data

Gossamer Bio Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.19, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.43, which is -91.32% below the recent high of -0.30 and -99.38% above the recent low of -6.84.

Score

Industry at a Glance

Previous score

6.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.44, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Gossamer Bio Inc is 9.00, with a high of 15.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.000

Target Price

+281.36%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Gossamer Bio Inc

GOSS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 7.21, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 2.57 and the support level at 2.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.03

Change

0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.027

Neutral

RSI(14)

47.983

Neutral

STOCH(KDJ)(9,3,3)

48.436

Neutral

ATR(14)

0.161

High Vlolatility

CCI(14)

-5.185

Neutral

Williams %R

37.778

Buy

TRIX(12,20)

-0.362

Sell

StochRSI(14)

87.992

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.346

Buy

MA10

2.376

Sell

MA20

2.336

Buy

MA50

2.613

Sell

MA100

2.181

Buy

MA200

1.654

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 77.47%, representing a quarter-over-quarter decrease of 4.07%. The largest institutional shareholder is The Vanguard, holding a total of 11.41M shares, representing 4.96% of shares outstanding, with 12.10% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Octagon Capital Advisors LP

18.35M

New Enterprise Associates (NEA)

18.09M

The Vanguard Group, Inc.

Star Investors

11.41M

+13.16%

BlackRock Institutional Trust Company, N.A.

11.15M

+295.30%

ARCH Venture Partners

8.06M

Fidelity Management & Research Company LLC

7.32M

-3.66%

Acadian Asset Management LLC

7.15M

+12.39%

683 Capital Management LLC

6.34M

+3.93%

Samsara BioCapital, LLC

6.13M

Palo Alto Investors LP

5.74M

-8.57%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.37, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.96. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.